| 3‐methyl‐1, 2, 3‐butanetricarboxylic acid: An atmospheric tracer for terpene secondary organic aerosol R Szmigielski, JD Surratt, Y Gómez‐González, P Van der Veken, ... Geophysical Research Letters 34 (24), 2007 | 290 | 2007 |
| Hydroxydicarboxylic acids: Markers for secondary organic aerosol from the photooxidation of α-pinene M Claeys, R Szmigielski, I Kourtchev, P Van der Veken, R Vermeylen, ... Environmental Science & Technology 41 (5), 1628-1634, 2007 | 255 | 2007 |
| Extended structure–activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP) K Jansen, L Heirbaut, R Verkerk, JD Cheng, J Joossens, P Cos, L Maes, ... Journal of medicinal chemistry 57 (7), 3053-3074, 2014 | 226 | 2014 |
| Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold K Jansen, L Heirbaut, JD Cheng, J Joossens, O Ryabtsova, P Cos, ... ACS medicinal chemistry letters 4 (5), 491-496, 2013 | 193 | 2013 |
| Terpenylic acid and related compounds from the oxidation of α-pinene: Implications for new particle formation and growth above forests M Claeys, Y Iinuma, R Szmigielski, JD Surratt, F Blockhuys, ... Environmental science & technology 43 (18), 6976-6982, 2009 | 180 | 2009 |
| Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ K Heyninck, M Lahtela-Kakkonen, P Van der Veken, G Haegeman, ... Biochemical pharmacology 91 (4), 501-509, 2014 | 165 | 2014 |
| Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases P Van der Veken, K Senten, I Kertèsz, I De Meester, AM Lambeir, ... Journal of medicinal chemistry 48 (6), 1768-1780, 2005 | 159 | 2005 |
| A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease TT Myöhänen, MJ Hannula, R Van Elzen, M Gerard, P Van Der Veken, ... British journal of pharmacology 166 (3), 1097-1113, 2012 | 126 | 2012 |
| Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy? M Berg, P Van der Veken, A Goeminne, A Haemers, K Augustyns Current medicinal chemistry 17 (23), 2456-2481, 2010 | 124 | 2010 |
| Novel ferroptosis inhibitors with improved potency and ADME properties S Hofmans, TV Berghe, L Devisscher, B Hassannia, S Lyssens, ... Journal of Medicinal Chemistry 59 (5), 2041-2053, 2016 | 113 | 2016 |
| Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy L Devisscher, S Van Coillie, S Hofmans, D Van Rompaey, K Goossens, ... Journal of medicinal chemistry 61 (22), 10126-10140, 2018 | 109 | 2018 |
| ClpP protease, a promising antimicrobial target C Moreno-Cinos, K Goossens, IG Salado, P Van Der Veken, H De Winter, ... International journal of molecular sciences 20 (9), 2232, 2019 | 108 | 2019 |
| Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator J Joossens, P Van der Veken, AM Lambeir, K Augustyns, A Haemers Journal of medicinal chemistry 47 (10), 2411-2413, 2004 | 100 | 2004 |
| CT-scan study of the incidence of sinus involvement and nasal anatomic variations in 196 children. PJ Van der Veken, PA Clement, TH Buisseret, B Desprechins, L Kaufman, ... Rhinology 28 (3), 177-184, 1990 | 98 | 1990 |
| Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors V Matheeussen, AM Lambeir, W Jungraithmayr, N Gomez, K Mc Entee, ... Clinica chimica acta 413 (3-4), 456-462, 2012 | 94 | 2012 |
| Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives I El Sayed, P Van der Veken, K Steert, L Dhooghe, S Hostyn, ... Journal of medicinal chemistry 52 (9), 2979-2988, 2009 | 94 | 2009 |
| Development of a Novel Chemical Probe for the Selective Enrichment of Phosphorylated Serine‐and Threonine‐Containing Peptides P van der Veken, EHC Dirksen, E Ruijter, RC Elgersma, AJR Heck, ... ChemBioChem 6 (12), 2271-2280, 2005 | 89 | 2005 |
| Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: Optimization of the P4 position J Joossens, P Van der Veken, G Surpateanu, AM Lambeir, I El-Sayed, ... Journal of medicinal chemistry 49 (19), 5785-5793, 2006 | 88 | 2006 |
| Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes K Augustyns, P Van der Veken, K Senten, A Haemers Expert Opinion on Therapeutic Patents 13 (4), 499-510, 2003 | 88 | 2003 |
| Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis V Matheeussen, Y Waumans, W Martinet, S Van Goethem, ... Basic research in cardiology 108, 1-14, 2013 | 86 | 2013 |
